---
provider: openscientist
model: openscientist-autonomous
cached: false
start_time: '2026-09-07T16:58:59.835002'
end_time: '2026-09-07T17:14:19.512609'
duration_seconds: 919.68
template_file: templates/disease_pathophysiology_research.md
template_sha: "1e7ea4ee817acfe1dda5f77fafe6f2e8b5927666"
template_variables:
  disease_name: Cleft Palate, Proliferative Retinopathy, and Developmental Delay
  mondo_id: MONDO:0033641
  category: Mendelian
provider_config:
  timeout: 3600
  max_retries: 3
  parameters:
    allowed_domains: []
    max_iterations: 5
    use_hypotheses: false
    investigation_mode: autonomous
    poll_interval: 30
    timeout: 3600
    save_artifacts: true
    artifact_max_bytes: 5242880
fell_back: true
requested_provider: falcon
provider_attempts:
- provider: falcon
  succeeded: false
  error_type: ProviderBillingError
  status_code: 402
  remedy: the account is out of credits
  retryable: false
- provider: openscientist
  succeeded: true
citation_count: 8
reference_validation:
  total_references: 8
  verified: 8
  not_found: 0
  unverifiable: 0
  confabulation_rate: 0.0
  relevance_assessed: 8
  on_topic: 3
  off_topic: 1
  off_topic_references:
  - PMID:35898500
  needs_review: true
  validator_version: 0.2.1
term_validation:
  total_terms: 22
  verified: 20
  not_found: 0
  obsolete: 0
  unverifiable: 2
  confabulation_rate: 0.0
  labels_checked: 10
  labels_matching: 5
  labels_mismatched: 2
  mislabelled_terms:
  - term_id: HP:0000175
    reported_labels:
    - Physical malformation
    ontology_label: Cleft palate
  - term_id: HP:0001999
    reported_labels:
    - Physical manifestation
    ontology_label: Abnormal facial shape
  labels_variant: 3
  unresolvable_prefixes:
  - Taxon
  needs_review: true
  adapter: 'ols:'
  validator_version: 0.4.5
artifact_count: 2
artifact_sources:
  openscientist_artifacts_zip: 2
artifacts:
- filename: final_report.html
  path: Cleft_Palate_Proliferative_Retinopathy_And_Developmental_Delay-deep-research-openscientist_artifacts/final_report.html
  media_type: text/html
  source: openscientist_artifacts_zip
  data_storage_id: null
  description: OpenScientist final report
- filename: final_report.pdf
  path: Cleft_Palate_Proliferative_Retinopathy_And_Developmental_Delay-deep-research-openscientist_artifacts/final_report.pdf
  media_type: application/pdf
  source: openscientist_artifacts_zip
  data_storage_id: null
  description: OpenScientist final report
---

## Question

# Disease Characteristics Research Template

## Target Disease
- **Disease Name:** Cleft Palate, Proliferative Retinopathy, and Developmental Delay
- **MONDO ID:** MONDO:0033641 (if available)
- **Category:** Mendelian

## Research Objectives

Please provide a comprehensive research report on **Cleft Palate, Proliferative Retinopathy, and Developmental Delay** covering all of the
disease characteristics listed below. This report will be used to populate a disease knowledge
base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, **suggested databases/resources** are listed. These are the first places
you should search for information on each topic.

---

### 1. Disease Information
> **Search first:** OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

- What is the disease? Provide a concise overview.
- What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
- What are the common synonyms and alternative names?
- Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

### 2. Etiology

- **Disease Causal Factors**: What are the primary causes? (genetic, environmental, infectious, mechanistic)
- **Risk Factors**:
  > **Search first:** PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases
  - Genetic risk factors (causal variants, susceptibility loci, modifier genes)
  - Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
- **Protective Factors**:
  > **Search first:** PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases
  - Genetic protective factors (protective variants, modifier alleles)
  - Environmental protective factors (diet, lifestyle, exposures that reduce risk)
- **Gene-Environment Interactions**: How do genetic and environmental factors interact to influence disease?
  > **Search first:** CTD, PubMed, PheGenI, GxE databases

### 3. Phenotypes
> **Search first:** HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide:
- **Phenotype type**: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities
  > For symptoms/signs: HPO, OMIM, Orphanet, PubMed
  > For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed
  > For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed
- **Phenotype characteristics**:
  > **Search first:** OMIM, Orphanet, HPO, PubMed
  - Age of symptom onset (neonatal, childhood, adult-onset, late-onset)
  - Symptom severity (mild, moderate, severe, variable)
  - Symptom progression (stable, progressive, episodic, fluctuating)
  - Frequency among affected individuals (percentage or qualitative)
- **Quality of life impact**: Effects on daily functioning and well-being (per-phenotype when possible)
  > **Search first:** EQ-5D database, SF-36, WHO QOL databases, PubMed
- Suggest HPO (Human Phenotype Ontology) terms for each phenotype

### 4. Genetic/Molecular Information

- **Causal Genes**: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)
  > **Search first:** OMIM, ClinVar, HGMD, Ensembl, NCBI Gene
- **Pathogenic Variants**:
  - Affected genes (gene symbols, HGNC IDs)
    > **Search first:** OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
  - Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines)
    > **Search first:** ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
  - Variant type/class (missense, frameshift, nonsense, splice-site, structural)
  - Allele frequency in population databases
    > **Search first:** gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
  - Somatic vs germline origin
    > **Search first:** COSMIC (somatic), ClinVar, ICGC, TCGA
  - Functional consequences (loss of function, gain of function, dominant negative)
- **Modifier Genes**: Genes that modify disease severity or expression
- **Epigenetic Information**: DNA methylation, histone modifications, chromatin changes affecting disease
  > **Search first:** ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
- **Chromosomal Abnormalities**: Large-scale genetic changes (aneuploidy, translocations, inversions)
  > **Search first:** DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

### 5. Environmental Information

- **Environmental Factors**: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)
  > **Search first:** CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases
- **Lifestyle Factors**: Behavioral factors (smoking, diet, exercise, alcohol consumption)
  > **Search first:** CDC databases, WHO, PubMed, NHANES
- **Infectious Agents**: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)
  > **Search first:** NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

### 6. Mechanism / Pathophysiology

**Present this section as an ordered causal chain first, then the detail below.**
Open with a numbered sequence of mechanistic steps running from the initiating
lesion (mutation, exposure, infection) to the clinical manifestation, one step per
line, each naming what it causes next. State the causal verb explicitly ("leads
to", "results in") and say where a step is inferred rather than demonstrated.
Where the mechanism branches, show the branch. The categories below are a
checklist of what to cover within those steps, not the organizing structure —
a step may draw on several of them, and a category may contribute to several
steps.

- **Molecular Pathways**: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)
  > **Search first:** KEGG, Reactome, WikiPathways, PathBank, BioCyc
- **Cellular Processes**: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)
  > **Search first:** Gene Ontology (GO), Reactome, KEGG, PubMed
- **Protein Dysfunction**: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)
  > **Search first:** UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold
- **Metabolic Changes**: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)
  > **Search first:** KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA
- **Immune System Involvement**: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)
  > **Search first:** ImmPort, Immunome Database, IEDB, Gene Ontology
- **Tissue Damage Mechanisms**: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)
  > **Search first:** PubMed, Gene Ontology, Reactome
- **Biochemical Abnormalities**: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)
  > **Search first:** BRENDA, UniProt, KEGG, OMIM, PubMed
- **Epigenetic Changes**: DNA methylation, histone modifications affecting gene expression in disease
  > **Search first:** ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
- **Molecular Profiling** (if available):
  - Transcriptomics/gene expression changes
    > **Search first:** GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
  - Proteomics findings
    > **Search first:** PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
  - Metabolomics signatures
    > **Search first:** MetaboLights, Metabolomics Workbench, HMDB, METLIN
  - Lipidomics alterations
    > **Search first:** LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
  - Genomic structural features
    > **Search first:** UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
- **Advanced Technologies** (if applicable):
  - Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity)
    > **Search first:** Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
  - Spatial transcriptomics findings
    > **Search first:** GEO, Spatial Research, Vizgen, 10x Genomics data
  - Multi-omics integration results
    > **Search first:** TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
  - Functional genomics screens (CRISPR, RNAi)
    > **Search first:** DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe:
- The causal chain from initial trigger to clinical manifestation
- Which mechanisms are upstream vs downstream
- What cell types and biological processes are involved
- Suggest GO terms for biological processes and CL terms for cell types

### 7. Anatomical Structures Affected

- **Organ Level**:
  - Primary organs directly affected
  - Secondary organ involvement (complications, secondary effects)
  - Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)
  > **Search first:** Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT
- **Tissue and Cell Level**:
  - Specific tissue types affected (epithelial, connective, muscle, nervous)
  - Specific cell populations targeted (with Cell Ontology terms)
  > **Search first:** Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB
- **Subcellular Level**:
  - Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)
  > **Search first:** Gene Ontology (Cellular Component), UniProt, Human Protein Atlas
- **Localization**:
  - Specific anatomical sites (with UBERON terms)
    > **Search first:** FMA, Uberon, NeuroNames (for brain), SNOMED CT
  - Lateralization (unilateral, bilateral, asymmetric)
    > **Search first:** HPO, clinical literature, imaging databases

### 8. Temporal Development

- **Onset**:
  - Typical age of onset (congenital, pediatric, adult, geriatric)
  - Onset pattern (acute, subacute, chronic, insidious)
  > **Search first:** OMIM, Orphanet, HPO, PubMed
- **Progression**:
  - Disease stages (early, intermediate, advanced, end-stage)
    > **Search first:** Cancer Staging Manual (AJCC), WHO classifications, PubMed
  - Progression rate (rapid, slow, variable)
  - Disease course pattern (episodic, relapsing-remitting, progressive, stable)
  - Disease duration (self-limited, chronic lifelong)
  > **Search first:** Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM
- **Patterns**:
  - Remission patterns (spontaneous, treatment-induced)
    > **Search first:** Clinical trial databases, disease registries, PubMed
  - Critical periods (time windows of vulnerability or opportunity for intervention)
    > **Search first:** PubMed, developmental biology databases, clinical guidelines

### 9. Inheritance and Population

- **Epidemiology**:
  - Prevalence (cases per 100,000 at given time)
  - Incidence (new cases per 100,000 per year)
  > **Search first:** Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries
- **For Genetic Etiology**:
  - Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic)
    > **Search first:** OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
  - Penetrance (complete, incomplete, age-dependent)
    > **Search first:** ClinVar, OMIM, PubMed, ClinGen
  - Expressivity (variable, consistent)
    > **Search first:** OMIM, ClinVar, PubMed
  - Genetic anticipation (increasing severity in successive generations)
    > **Search first:** OMIM, PubMed (especially for repeat expansion disorders)
  - Germline mosaicism
    > **Search first:** ClinVar, OMIM, genetic counseling literature, PubMed
  - Founder effects (population-specific mutations)
    > **Search first:** gnomAD, population genetics databases, PubMed
  - Consanguinity role
    > **Search first:** OMIM, population studies, genetic counseling resources
  - Carrier frequency
    > **Search first:** gnomAD, carrier screening databases, GeneReviews, GTR
- **Population Demographics**:
  - Affected populations (ethnic or demographic groups with higher prevalence)
    > **Search first:** gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
  - Geographic distribution (endemic areas, regional variation)
    > **Search first:** WHO, CDC, GBD, Orphanet, geographic epidemiology databases
  - Geographic distribution of specific variants
  - Sex ratio (male:female)
    > **Search first:** Disease registries, OMIM, PubMed, epidemiological databases
  - Age distribution of affected individuals
    > **Search first:** CDC, disease registries, SEER, Orphanet

### 10. Diagnostics

- **Clinical Tests**:
  - Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays)
    > **Search first:** LOINC, LabTests Online, PubMed
  - Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers)
    > **Search first:** FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
  - Imaging studies (X-ray, CT, MRI, PET, ultrasound)
    > **Search first:** RadLex, DICOM, Radiopaedia, imaging databases
  - Functional tests (pulmonary function, cardiac stress tests)
    > **Search first:** LOINC, clinical guidelines, PubMed
  - Electrophysiology (EEG, EMG, ECG, nerve conduction studies)
    > **Search first:** LOINC, clinical neurophysiology databases, PubMed
  - Biopsy findings (histopathology, immunohistochemistry)
    > **Search first:** SNOMED CT, College of American Pathologists resources, PubMed
  - Pathology findings (microscopic examination)
    > **Search first:** SNOMED CT, Digital Pathology databases, PubMed
- **Genetic Testing**:
  > **Search first:** GTR (Genetic Testing Registry), GeneReviews, ClinGen
  - Overview of recommended genetic testing approach
  - Whole genome sequencing (WGS) utility
    > **Search first:** GTR, ClinVar, GEL (Genomics England), gnomAD
  - Whole exome sequencing (WES) utility
    > **Search first:** GTR, ClinVar, OMIM, GeneMatcher
  - Gene panels (which panels, which genes)
    > **Search first:** GTR, ClinVar, laboratory-specific databases
  - Single gene testing
    > **Search first:** GTR, ClinVar, OMIM, GeneReviews
  - Chromosomal microarray (CMA)
    > **Search first:** DECIPHER, ClinVar, dbVar, ECARUCA
  - Karyotyping
    > **Search first:** Chromosome Abnormality Database, ClinVar, cytogenetics resources
  - FISH
    > **Search first:** ClinVar, cytogenetics databases, PubMed
  - Mitochondrial DNA testing
    > **Search first:** MITOMAP, MSeqDR, ClinVar, GTR
  - Repeat expansion testing
    > **Search first:** GTR, ClinVar, repeat expansion databases, PubMed
- **Omics-Based Diagnostics** (if applicable):
  - RNA sequencing / transcriptomics
    > **Search first:** GEO, ArrayExpress, GTEx, RNA-seq databases
  - Proteomics
    > **Search first:** PRIDE, ProteomeXchange, FDA Biomarker database
  - Metabolomics
    > **Search first:** MetaboLights, Metabolomics Workbench, HMDB
  - Epigenomics
    > **Search first:** GEO, ENCODE, Roadmap Epigenomics, MethBase
  - Liquid biopsy
    > **Search first:** COSMIC, ClinVar, liquid biopsy databases, PubMed
- **Clinical Criteria**:
  - Standardized diagnostic criteria (DSM, ICD, society guidelines)
    > **Search first:** DSM-5, ICD-11, clinical society guidelines, UpToDate
  - Differential diagnosis (other conditions to rule out, with distinguishing features)
    > **Search first:** DynaMed, UpToDate, clinical decision support systems
- **Screening**:
  - Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening)
    > **Search first:** ACMG recommendations, CDC newborn screening, GTR

### 11. Outcome/Prognosis

- **Survival and Mortality**:
  - Survival rate (5-year, 10-year, overall)
    > **Search first:** SEER, cancer registries, disease-specific registries, PubMed
  - Life expectancy (with and without treatment if applicable)
    > **Search first:** Orphanet, disease registries, actuarial databases, PubMed
  - Mortality rate
    > **Search first:** CDC, WHO, GBD, national mortality databases
  - Disease-specific mortality (deaths directly attributable to disease)
    > **Search first:** Disease registries, CDC Wonder, GBD, PubMed
- **Morbidity and Function**:
  - Morbidity (disease-related disability and health impacts)
    > **Search first:** GBD, WHO, disability databases, PubMed
  - Disability outcomes (long-term functional impairments)
    > **Search first:** ICF (International Classification of Functioning), disability registries
  - Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools)
    > **Search first:** EQ-5D database, SF-36, PROMIS, PubMed
- **Disease Course**:
  - Complications (secondary problems: infections, organ failure, etc.)
    > **Search first:** ICD codes, disease registries, clinical databases, PubMed
  - Recovery potential (likelihood and extent of recovery, with vs without treatment)
    > **Search first:** Natural history studies, rehabilitation databases, PubMed
- **Prediction**:
  - Prognostic factors (age, disease severity, biomarkers, treatment response)
    > **Search first:** Prognostic models databases, clinical calculators, PubMed
  - Prognostic biomarkers (molecular markers predicting disease course)
    > **Search first:** FDA Biomarker database, PubMed, cancer prognostic databases

### 12. Treatment

- **Pharmacotherapy**:
  - Pharmacological treatments (drug names, drug classes, mechanisms of action)
    > **Search first:** DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
  - Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity)
    > **Search first:** PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
- **Advanced Therapeutics**:
  - Gene therapy (viral vectors, CRISPR, gene replacement, gene editing)
    > **Search first:** ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
  - Cell therapy (stem cell transplant, CAR-T, cellular therapeutics)
    > **Search first:** ClinicalTrials.gov, FDA cell therapy database, FACT standards
  - RNA-based therapies (ASOs, siRNA, mRNA therapies)
    > **Search first:** ClinicalTrials.gov, FDA approvals, PubMed
  - Targeted therapies (treatments directed at specific molecular targets)
    > **Search first:** My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
  - Immunotherapies (checkpoint inhibitors, monoclonal antibodies)
    > **Search first:** Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
- **Surgical and Interventional**:
  - Surgical interventions (types of surgery, timing, outcomes)
    > **Search first:** CPT codes, surgical registries, clinical guidelines, PubMed
- **Supportive and Rehabilitative**:
  - Supportive care (symptom management, pain control, nutrition)
    > **Search first:** Clinical guidelines, Cochrane Library, PubMed
  - Rehabilitation (physical therapy, occupational therapy, speech therapy)
    > **Search first:** Rehabilitation medicine databases, clinical guidelines, PubMed
- **Experimental**:
  - Experimental treatments in clinical trials (with NCT identifiers if available)
    > **Search first:** ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
- **Treatment Outcomes**:
  - Treatment response rates
    > **Search first:** Clinical trial databases, FDA reviews, systematic reviews, PubMed
  - Side effects and adverse events
    > **Search first:** FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
- **Treatment Strategy**:
  - Treatment algorithms (clinical pathways, decision trees)
    > **Search first:** Clinical practice guidelines, NCCN Guidelines, UpToDate
  - Combination therapies
    > **Search first:** ClinicalTrials.gov, treatment guidelines, PubMed
  - Personalized medicine approaches (genotype-guided treatment)
    > **Search first:** My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest NCIT (NCI Thesaurus) clinical-intervention terms where applicable.

### 13. Prevention

- **Prevention Levels**:
  - Primary prevention (preventing disease occurrence: vaccination, risk factor modification)
    > **Search first:** CDC, WHO, USPSTF recommendations, Cochrane Library
  - Secondary prevention (early detection and treatment: screening programs, early intervention)
    > **Search first:** USPSTF, CDC screening guidelines, WHO
  - Tertiary prevention (preventing complications in those with disease)
    > **Search first:** Clinical guidelines, disease management protocols, PubMed
- **Immunization**: Vaccine strategies (if applicable)
  > **Search first:** CDC vaccine schedules, WHO immunization, FDA vaccine database
- **Screening and Early Detection**:
  - Screening programs (population-based: newborn screening, cancer screening)
    > **Search first:** CDC screening programs, USPSTF, cancer screening databases
  - Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing)
    > **Search first:** ACMG recommendations, ACOG guidelines, GTR
  - Risk stratification (identifying high-risk individuals for targeted prevention)
    > **Search first:** Risk prediction models, clinical calculators, PubMed
- **Behavioral Interventions**: Lifestyle modifications to reduce risk
  > **Search first:** CDC, WHO, behavioral intervention databases, Cochrane Library
- **Counseling**: Genetic counseling (risk assessment, family planning guidance)
  > **Search first:** NSGC resources, ACMG guidelines, GeneReviews
- **Public Health**:
  - Public health interventions (sanitation, vector control, health education)
    > **Search first:** CDC, WHO, public health databases, PubMed
  - Environmental interventions (reducing environmental risk factors)
    > **Search first:** EPA databases, WHO environmental health, PubMed
- **Prophylaxis**: Preventive medications or procedures
  > **Search first:** Clinical guidelines, FDA approvals, PubMed

### 14. Other Species / Natural Disease

- **Taxonomy**: Species affected (with NCBI Taxon identifiers)
  > **Search first:** NCBI Taxonomy
- **Breed**: Specific breeds affected (with VBO identifiers if applicable)
  > **Search first:** VBO (Vertebrate Breed Ontology)
- **Gene**: Orthologous genes in other species (with NCBI Gene IDs)
  > **Search first:** NCBI Gene
- **Natural Disease**:
  - Naturally occurring disease in other species (companion animals, wildlife)
    > **Search first:** OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
  - Veterinary relevance and importance in animal health
    > **Search first:** OMIA, veterinary databases, PubMed
- **Comparative Biology**:
  - Comparative pathology (similarities and differences across species)
    > **Search first:** OMIA, comparative pathology databases, PubMed
  - Evolutionary conservation of disease mechanisms
    > **Search first:** HomoloGene, OrthoMCL, Alliance of Genome Resources
- **Transmission** (if applicable):
  - Zoonotic potential
    > **Search first:** CDC zoonotic diseases, WHO zoonoses, GIDEON
  - Cross-species susceptibility
    > **Search first:** NCBI Taxonomy, veterinary databases, PubMed

### 15. Model Organisms

- **Model Types**:
  - Model organism type (mammalian, invertebrate, cellular, in vitro)
    > **Search first:** Alliance of Genome Resources, model organism databases
  - Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs)
    > **Search first:** MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
  - Induced models (drug treatment, surgical intervention, environmental manipulation)
    > **Search first:** MGI, model organism databases, PubMed
- **Genetic Models**:
  - Types available (knockout, knock-in, transgenic, conditional, humanized)
    > **Search first:** MGI, IMPC, KOMP, EuMMCR, IMSR
- **Model Characteristics**:
  - Phenotype recapitulation (how well model reproduces human disease features)
    > **Search first:** Model organism databases, comparative studies, PubMed
  - Model limitations (aspects of human disease not captured)
    > **Search first:** Model organism databases, PubMed, review articles
- **Applications**:
  - Research applications (what aspects of disease can be studied)
    > **Search first:** Model organism databases, PubMed
- **Resources**:
  - Model databases
    > **Search first:** MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

---

## Citation Requirements

- Cite primary literature (PMID preferred) for all mechanistic and clinical claims
- Prioritize recent reviews and landmark papers
- Include direct quotes from abstracts where possible to support key statements
- Distinguish evidence source types: human clinical, model organism, in vitro, computational

## Output Format

Structure your response as a comprehensive narrative organized by the sections above.
For each section, provide:
- Factual content with specific details (numbers, percentages, gene names, variant nomenclature)
- Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, NCIT, MONDO) where applicable
- Evidence citations with PMIDs
- Direct quotes from abstracts to support key claims
- Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with:
- Pathophysiology descriptions with causal chains
- Gene/protein annotations (HGNC, GO terms)
- Phenotype associations (HP terms) with frequencies
- Cell type involvement (CL terms)
- Anatomical locations (UBERON terms)
- Chemical entities (CHEBI terms)
- Treatment annotations (NCIT terms)
- Evidence items with PMIDs and exact abstract quotes
- Epidemiology, prognosis, diagnostic, and prevention information
- Animal model descriptions with phenotype recapitulation details


## Output

# Cleft Palate, Proliferative Retinopathy, and Developmental Delay (MONDO:0033641): A Comprehensive Disease Report

## Summary

**Cleft palate, proliferative retinopathy, and developmental delay** (MONDO:0033641) is an **ultra-rare autosomal-recessive Mendelian syndrome** caused by **biallelic loss-of-function variants in *LRRC32*** (encoding **GARP**, Glycoprotein A Repetitions Predominant; chromosome 11q13.5). To date, the disorder has been reported in only approximately **four patients from consanguineous families**, making it one of the least-characterized Mendelian conditions in the medical literature. The disease was first delineated by Harel and colleagues in 2019, who identified a homozygous stop-gain variant (*LRRC32* c.1630C>T; p.(Arg544Ter)) segregating in two consanguineous families with the defining triad of developmental delay, cleft palate, and proliferative retinopathy. A second, independent family was reported in 2022 with a distinct homozygous missense variant, confirming the gene–disease association and expanding the phenotype to include severe pre- and postnatal growth retardation and dysmorphic features.

The **mechanistic basis** of the syndrome is loss of GARP function. GARP is a cell-surface docking receptor that binds and presents the **latent form of transforming growth factor-beta (TGF-β)** on the plasma membrane, where it is subsequently activated in an integrin-dependent manner (chiefly via αvβ8/αvβ6) to release mature, signaling-competent TGF-β. Loss of GARP therefore diminishes **latent TGF-β presentation and activation**, reducing downstream **SMAD2/3 signaling**. This mechanism has been directly demonstrated in the developing secondary palate: *Garp/Lrrc32*-null mice show reduced SMAD2 phosphorylation and failed apoptosis in the palatal medial edge epithelium (MEE), causing cleft palate and phenocopying *Tgfb3*-null mice. Because the TGF-β pathway is also essential for retinal and central nervous system development, the retinopathy and neurodevelopmental features are attributed — largely by inference — to the same signaling deficit operating in those tissues.

There is **no targeted or disease-modifying therapy**. Management is entirely **supportive and multidisciplinary**: surgical palatoplasty for the cleft palate, vitreoretinal surgery/ophthalmologic management for the proliferative retinopathy, and developmental/rehabilitative support for the neurodevelopmental delay, combined with genetic counseling (25% sibling recurrence risk in an autosomal-recessive pedigree). Because of the extreme rarity — no new cases have been described since 2022 — much of the clinical natural history, epidemiology, prognosis, and treatment response data remain undefined, and this report explicitly flags those gaps.

---

## Key Findings

### Finding 1 — *LRRC32* (GARP) biallelic loss-of-function is the cause (autosomal recessive)

The syndrome is caused by **biallelic (homozygous) loss-of-function variants in *LRRC32***, transmitted in an **autosomal-recessive** pattern. Harel et al. (2019) identified a **homozygous stop-gain variant, *LRRC32* c.1630C>T; p.(Arg544Ter)**, segregating in **two consanguineous families comprising three affected individuals**, all presenting with the triad of developmental delay, cleft palate, and proliferative retinopathy. The original report states directly: *"We identified a homozygous stop-gain variant in LRRC32 (c.1630C>T; p.(Arg544Ter)) in two families with developmental delay, cleft palate, and proliferative retinopathy"* ([PMID: 30976112](https://pubmed.ncbi.nlm.nih.gov/30976112/)).

A **second, independent line of evidence** came from Hexner-Erlichman et al. (2022), who used whole-exome sequencing to identify a **distinct homozygous missense variant** — a substitution of a highly conserved isoleucine to threonine — in a **fourth patient** from another consanguineous family: *"Whole exome sequencing (WES) revealed a very rare homozygous missense variant in the LRRC32 gene, which resulted in substitution of a highly conserved isoleucine to threonine"* ([PMID: 35656379](https://pubmed.ncbi.nlm.nih.gov/35656379/)). This second family, harboring a different variant type (missense vs. nonsense) yet producing an overlapping phenotype, provides **allelic heterogeneity** that reinforces the causal gene–disease relationship. Both families were consanguineous, consistent with a rare recessive disorder enriched in inbred pedigrees.

**Evidence source types:** human clinical (two independent reports); genetic (WES/segregation).

### Finding 2 — Mechanism: GARP loss impairs latent TGF-β3 presentation/activation, reducing SMAD2 signaling and apoptosis in palatal medial edge epithelium

The molecular mechanism was established in a mouse model by Wu et al. (2017). ***Garp/Lrrc32*-null mice die within 24 hours of birth with an isolated failure of secondary palate fusion.** At embryonic day 14.5 (E14.5), the palatal **medial edge epithelial (MEE)** cells show **decreased apoptosis** and **reduced SMAD2 phosphorylation**: *"we observed decreased apoptosis and SMAD2 phosphorylation in the medial edge epithelial cells of the palatal shelf of GARP KO embryos at embryonic day 14.5"* ([PMID: 28912269](https://pubmed.ncbi.nlm.nih.gov/28912269/)).

GARP and TGFβ3 co-localize in MEE cells, physically interact, and GARP is required for cell-surface display of membrane-associated latent TGFβ3: *"GARP is indispensable for the surface expression of membrane-associated latent TGFβ3"* ([PMID: 28912269](https://pubmed.ncbi.nlm.nih.gov/28912269/)). Critically, the GARP-null palatal defect **phenocopies the *Tgfb3*-null mouse**: *"the failure to develop the secondary palate and concurrent reduction of SMAD phosphorylation without other defects in GARP KO mice phenocopied TGFβ3 KO mice"* ([PMID: 28912269](https://pubmed.ncbi.nlm.nih.gov/28912269/)). This places GARP squarely upstream of TGF-β3/SMAD signaling in palatogenesis and provides the direct mechanistic explanation for the cleft-palate component of the human syndrome.

More broadly, GARP presents latent TGF-β1 on the surface of regulatory T cells and platelets, where activation requires **integrin αvβ8** and release (or, per newer models, allosteric exposure) of mature TGF-β — a mechanism corroborated by multiple structural and immunological studies (see Evidence Base).

**Evidence source types:** model organism (mouse knockout); in vitro (co-localization, interaction, SMAD phosphorylation assays).

### Finding 3 — *LRRC32* is recessive-compatible in gnomAD; the recurrent pathogenic allele p.(Arg544Ter) is ultra-rare with no homozygotes

Population-genetic analysis of gnomAD is fully consistent with a rare recessive disease model. For *LRRC32* (ENSG00000137507, GRCh38 chr11:76,657,524–76,670,747), gnomAD v4 reports **pLI = 0.66** and an **observed/expected loss-of-function ratio (oe_lof) = 0.33** (90% CI 0.17–0.70), with **5 observed vs. 15.0 expected LoF alleles** (lof_z = 2.19). These values indicate that the gene tolerates heterozygous LoF variation (i.e., carriers are viable and present in the population), exactly as expected for a recessive disorder where only biallelic loss is pathogenic.

The recurrent disease allele **c.1630C>T p.(Arg544Ter) (rs369867819)** is **ultra-rare**, with an exome allele frequency ≈ **1.37 × 10⁻⁶** (2 heterozygous alleles observed) and **no homozygotes** in gnomAD. A missense change at the same codon, p.Arg544Gln, is also seen at very low frequency (AF ≈ 2.05 × 10⁻⁶). The absence of homozygotes in a reference database of >700,000 individuals is precisely what is expected for an ultra-rare, severe recessive condition and adds population-level support to the pathogenicity of the reported allele.

**Evidence source types:** computational/population-genetic (gnomAD v4 constraint metrics and allele frequencies).

| Metric (gnomAD v4, *LRRC32*) | Value | Interpretation |
|---|---|---|
| pLI | 0.66 | Moderate LoF intolerance |
| oe_lof (90% CI) | 0.33 (0.17–0.70) | Some constraint; recessive-compatible |
| Observed / Expected LoF | 5 / 15.0 | Fewer LoF than expected |
| lof_z | 2.19 | Mild constraint |
| p.(Arg544Ter) exome AF | ≈1.37 × 10⁻⁶ | Ultra-rare |
| p.(Arg544Ter) homozygotes | 0 | Consistent with severe recessive disease |

### Finding 4 — Clinical triad and TGF-β developmental basis; neonatal lethality in the mouse null limits modeling

The **defining clinical triad** is **cleft palate + proliferative retinopathy + developmental delay**, congenital in onset, reported in two consanguineous families (three individuals; Harel et al. 2019). The unifying developmental explanation is the **TGF-β pathway**, which is essential for both palatogenesis and retinal development: *"The transforming growth factor-beta (TGFβ) signaling pathway is essential for palatogenesis and retinal development"* ([PMID: 30976112](https://pubmed.ncbi.nlm.nih.gov/30976112/)).

A key limitation of the animal model is that **complete *Garp*-null mice die within 24 hours of birth**: *"Garp-null mice have palate defects and die within 24 h after birth"* ([PMID: 30976112](https://pubmed.ncbi.nlm.nih.gov/30976112/)). This neonatal lethality means the mouse recapitulates the **palatal** defect but **cannot model the postnatal ocular (proliferative retinopathy) or neurodevelopmental (developmental delay)** features, which require postnatal survival to manifest and assess. The 2022 fourth patient additionally exhibited **severe pre- and postnatal growth retardation and dysmorphic features**, expanding the recognized phenotypic spectrum beyond the original triad.

**Evidence source types:** human clinical (phenotype); model organism (lethality/limitation).

---

## Full Section-by-Section Report

### 1. Disease Information

**Overview.** MONDO:0033641 is an ultra-rare, congenital, autosomal-recessive multisystem syndrome defined by the co-occurrence of **cleft palate**, **proliferative retinopathy**, and **developmental delay**. It results from complete or near-complete loss of GARP (encoded by *LRRC32*), a chaperone/docking protein for latent TGF-β. The disorder was newly delineated as a Mendelian entity in 2019.

**Key identifiers.**
- **MONDO:** MONDO:0033641
- **Gene:** *LRRC32* (HGNC:4161), also known as **GARP**
- **OMIM:** The molecular entity is captured through the *LRRC32* gene entry (OMIM \*137207); a discrete OMIM phenotype MIM number, if assigned, post-dates the original 2019 report. (Not definitively available.)
- **Orphanet / ICD-10 / ICD-11 / MeSH:** No dedicated code was identified for this specific triad syndrome; component phenotypes map to generic terms (cleft palate ICD-10 Q35; congenital retinal disorders; unspecified developmental delay). (Not available as a unified code.)

**Synonyms / alternative names.** "LRRC32-related syndrome"; "GARP deficiency syndrome"; "cleft palate–proliferative retinopathy–developmental delay syndrome."

**Data provenance.** All information is derived from **aggregated disease-level and case-report literature** (two peer-reviewed clinical/genetic reports describing four patients) plus a mechanistic mouse study and public population databases — **not** from large EHR cohorts.

### 2. Etiology

**Causal factors — genetic.** The sole established cause is **biallelic loss-of-function of *LRRC32*/GARP**. Two variant classes are documented: a **nonsense** allele (p.Arg544Ter) and a **missense** allele (conserved Ile→Thr) ([PMID: 30976112](https://pubmed.ncbi.nlm.nih.gov/30976112/); [PMID: 35656379](https://pubmed.ncbi.nlm.nih.gov/35656379/)).

**Genetic risk factors.** **Consanguinity** is the principal risk factor, as expected for an ultra-rare recessive disorder; both reported families were consanguineous. Carrier status (heterozygosity) confers no known phenotype.

**Environmental risk factors / protective factors / gene–environment interactions.** **Not available / not applicable.** No environmental contributors, protective alleles, dietary factors, or gene–environment interactions have been described for this monogenic disorder. Given the deterministic Mendelian etiology, environmental modifiers are unlikely to be primary drivers, though they cannot be excluded as modifiers of severity.

### 3. Phenotypes

| Phenotype | Type | Suggested HPO | Onset | Frequency (of ~4 reported) |
|---|---|---|---|---|
| Cleft palate | Physical malformation | HP:0000175 | Congenital | Core triad feature |
| Proliferative retinopathy | Clinical/ophthalmologic sign | HP:0000556 (retinopathy) / HP:0008046 (abnormal retinal vasculature) | Congenital/early | Core triad feature |
| Developmental delay / intellectual disability | Neurodevelopmental | HP:0001263 (global developmental delay) | Infancy | Core triad feature |
| Severe pre-/postnatal growth retardation | Growth abnormality | HP:0001511 / HP:0008897 | Prenatal onset | 4th patient (2022) |
| Dysmorphic facial features | Physical manifestation | HP:0001999 | Congenital | 4th patient (2022) |

**Characteristics.** Onset is **congenital** for the triad. Severity appears **moderate to severe** and the course is best described as **stable/static** (a congenital malformation syndrome rather than a progressive degeneration), although the proliferative retinopathy component carries risk of progression to vision loss without intervention. **Frequency data are qualitative only**, given the tiny patient count.

**Quality-of-life impact.** Not formally measured (no EQ-5D/SF-36/PROMIS data). By clinical inference, cleft palate impairs feeding and speech; proliferative retinopathy threatens vision; developmental delay affects cognition, communication, and independence — collectively implying substantial lifelong QoL burden. (Quantitative data **not available**.)

### 4. Genetic / Molecular Information

- **Causal gene:** ***LRRC32*** (GARP), HGNC:4161, located at **11q13.5** (GRCh38 chr11:76,657,524–76,670,747; ENSG00000137507).
- **Pathogenic variants:**
  - **c.1630C>T; p.(Arg544Ter)** — nonsense/stop-gain; rs369867819; germline; homozygous in affected individuals; predicted loss of function (truncation). gnomAD exome AF ≈ 1.37 × 10⁻⁶, no homozygotes.
  - **Homozygous missense, conserved Ile→Thr** — germline; function-impairing; reported 2022.
- **Variant classification:** Consistent with **pathogenic/likely pathogenic** per ACMG criteria (ultra-rare, homozygous in affected consanguineous families, segregation, LoF mechanism, functional support from mouse ortholog).
- **Somatic vs. germline:** **Germline** (constitutional, inherited).
- **Functional consequence:** **Loss of function** — reduced/absent GARP-mediated latent TGF-β presentation.
- **Modifier genes / epigenetics / chromosomal abnormalities:** **Not available.** No modifier loci, methylation changes, or large-scale cytogenetic rearrangements have been implicated; the disorder is a single-gene point-mutation disorder.

### 5. Environmental Information

**Not applicable.** No environmental factors, lifestyle contributors, toxins, or infectious agents are associated with this monogenic recessive syndrome. (No CTD/TOXNET or exposure associations identified.)

### 6. Mechanism / Pathophysiology

**Ordered causal chain (initiating lesion → clinical manifestation):**

1. **Biallelic LoF mutation in *LRRC32*** (nonsense p.Arg544Ter or function-impairing missense) → **leads to** loss/severe reduction of functional GARP protein. *(Demonstrated: human genetics.)*
2. Loss of GARP → **results in** failure to display membrane-associated **latent TGF-β (esp. TGF-β3 in palate; TGF-β1 in immune cells)** on the cell surface. *(Demonstrated in mouse MEE: GARP indispensable for surface latent TGFβ3.)*
3. Absent surface latent TGF-β → **prevents** integrin (αvβ8/αvβ6)-mediated activation and local presentation of mature TGF-β. *(Demonstrated/mechanistically established.)*
4. Reduced local TGF-β activity → **leads to** decreased **TGF-β receptor engagement and SMAD2/3 phosphorylation**. *(Demonstrated: reduced pSMAD2 in E14.5 palatal MEE.)*
5a. Reduced SMAD2 signaling in palatal MEE → **causes** failed programmed cell death (apoptosis) of the medial edge epithelium → **prevents** palatal shelf fusion → **cleft palate**. *(Demonstrated; phenocopies Tgfb3-null.)*
5b. Reduced TGF-β/SMAD signaling in the developing retina → **inferred to** disrupt retinal vascular/neuroepithelial development → **proliferative retinopathy**. *(Inferred, not directly demonstrated.)*
5c. Reduced TGF-β/SMAD signaling in the developing CNS → **inferred to** impair neurodevelopment → **developmental delay** (± growth retardation/dysmorphism). *(Inferred.)*

**Molecular pathways.** Core pathway is **TGF-β/SMAD2-3 signaling** (KEGG hsa04350; Reactome "Signaling by TGF-beta Receptor Complex"). GARP (LRRC32) functions as the latent-TGF-β docking receptor upstream of receptor activation. Integrin αvβ8-mediated activation is the proximal activation step.

**Cellular processes.** **Apoptosis** of the palatal medial edge epithelium is the key demonstrated cellular event (GO:0006915 apoptotic process; specifically epithelial cell apoptosis during palate fusion). Loss of GARP → reduced MEE apoptosis → persistent midline epithelial seam → cleft.

**Protein dysfunction.** GARP is a leucine-rich-repeat transmembrane protein; the p.Arg544Ter truncation removes C-terminal/transmembrane-proximal sequence required for surface presentation, and the conserved Ile→Thr missense is predicted to impair folding/function — both yielding **loss of function** (failure to chaperone/present latent TGF-β).

**Immune system involvement.** GARP is the principal presenter of latent TGF-β1 on **regulatory T cells and platelets**; in cancer/immunology contexts it drives immunosuppression. In this developmental syndrome the immune role is secondary, but the same biochemistry (GARP:latent-TGF-β:integrin activation) underlies the disease. No overt immunodeficiency/autoimmunity has been reported in patients.

**Suggested ontology terms.** GO:0007179 (transforming growth factor beta receptor signaling pathway), GO:0006915 (apoptotic process), GO:0060021 (palate development), GO:0001654 (eye development). CL terms: epithelial cell **CL:0000066** (palatal medial edge epithelium), retinal pigment epithelial cell **CL:0002586**, neuron **CL:0000540**. UBERON: secondary palate **UBERON:0001716**, retina **UBERON:0000966**, brain **UBERON:0000955**. CHEBI: TGF-β is a protein (not a small molecule), so no CHEBI term applies to the ligand itself.

### 7. Anatomical Structures Affected

- **Primary organs:** secondary **palate** (UBERON:0001716), **retina/eye** (UBERON:0000966 retina; UBERON:0000970 eye), **brain/CNS** (UBERON:0000955).
- **Body systems:** craniofacial/digestive-respiratory interface (palate), visual system, central nervous system; with growth (in the 2022 patient).
- **Tissue/cell level:** **palatal medial edge epithelium** (epithelial tissue), **retinal cells** (including retinal pigment epithelium and vasculature), **neural cells**.
- **Subcellular:** GARP is a **plasma-membrane** protein (GO:0005886 plasma membrane); the functional defect is at the **cell surface** (loss of surface latent-TGF-β complex).
- **Localization / lateralization:** cleft palate is typically **midline**; retinopathy and developmental delay are **bilateral**. Specific laterality data are limited given the small cohort.

### 8. Temporal Development

- **Onset:** **congenital** for the triad; growth retardation is **prenatal-onset** in the 2022 patient.
- **Onset pattern:** developmental/structural (present at birth), not acute.
- **Progression:** the malformation syndrome is largely **static**; however, proliferative retinopathy can **progress** to retinal detachment/vision loss without ophthalmologic intervention.
- **Disease duration:** **chronic, lifelong**.
- **Critical periods:** the palatal defect originates during **secondary palate fusion (~E14.5 in mouse; ~weeks 8–12 of human gestation)** — a window inaccessible to postnatal intervention. Postnatal critical windows exist for **retinal intervention** and **early developmental/rehabilitative therapy**.

### 9. Inheritance and Population

- **Inheritance:** **autosomal recessive** (biallelic *LRRC32* LoF); both families consanguineous.
- **Penetrance:** appears **complete** in reported homozygotes (all biallelic individuals affected), though based on very few cases.
- **Expressivity:** **variable** — the 2022 patient showed additional growth retardation/dysmorphism beyond the core triad.
- **Consanguinity:** central to disease occurrence.
- **Carrier frequency:** ultra-low; the recurrent p.(Arg544Ter) allele has gnomAD AF ≈ 1.37 × 10⁻⁶ with **no homozygotes** — consistent with a severe, ultra-rare recessive condition.
- **Founder effects / anticipation / mosaicism:** No founder effect, genetic anticipation, or germline mosaicism has been documented. Anticipation is not expected (not a repeat-expansion disorder).
- **Epidemiology:** **prevalence and incidence are undefined** — fewer than ~5 patients reported worldwide. **Sex ratio, geographic distribution, and age distribution** cannot be reliably estimated.

### 10. Diagnostics

- **Recommended approach:** molecular genetic testing. **Whole-exome sequencing (WES)** was the diagnostic modality in both the original and second reports and is the highest-yield test; **whole-genome sequencing (WGS)** is a reasonable alternative. Targeted single-gene testing of *LRRC32* is appropriate once the phenotype is recognized or a familial variant is known.
- **Variant interpretation:** confirm biallelic status; classify per **ACMG/AMP** with ClinVar/segregation support.
- **Clinical/imaging workup:** ophthalmologic examination and retinal imaging (to characterize the proliferative retinopathy), craniofacial/palate examination, and developmental assessment. **Chromosomal microarray/karyotype** are typically normal (point-mutation disorder) but may be performed to exclude structural mimics.
- **Differential diagnosis:** other syndromic cleft-palate disorders (e.g., *TGFB3*-related, Van der Woude, **Stickler syndrome** — which also features cleft palate plus retinal detachment and is thus an important mimic), and other syndromic retinopathy/developmental-delay conditions. Molecular testing distinguishes them.
- **Screening:** for at-risk consanguineous families with a known familial variant, **carrier testing** and **cascade/prenatal testing** are available. No population newborn screening exists.

### 11. Outcome / Prognosis

Formal survival, mortality, and quality-of-life outcome data are **not available** given the rarity. Inferences: the human disorder is compatible with **postnatal survival** (unlike the neonatal-lethal complete mouse null, human patients survive infancy — likely reflecting residual/hypomorphic function or species differences). Prognosis is shaped by the **severity of the retinopathy** (vision-threatening) and the **degree of developmental delay** (affecting long-term function), plus feeding/speech consequences of the cleft palate. Recovery of the structural defects is not spontaneous; surgical/rehabilitative intervention improves function. Prognostic biomarkers are **not established**.

### 12. Treatment

**No targeted or disease-modifying therapy exists.** Management is **supportive and multidisciplinary**:

| Domain | Intervention | Suggested NCIT concept |
|---|---|---|
| Cleft palate | **Palatoplasty** (surgical repair); feeding support; speech therapy | Cleft palate repair; Speech therapy |
| Proliferative retinopathy | Ophthalmologic surveillance; **vitreoretinal surgery**; consider anti-VEGF/laser per lesion type | Vitrectomy; Laser therapy |
| Developmental delay | **Early developmental intervention**; physical/occupational/speech therapy; special education | Rehabilitation therapy |
| Family | **Genetic counseling** (25% sibling recurrence) | Genetic counseling |

**Pharmacotherapy / pharmacogenomics / gene therapy / cell therapy / RNA therapy / immunotherapy:** **None approved or in trials** for this disorder specifically. No NCT-registered trials target MONDO:0033641. (Note: the broader GARP–TGF-β axis is an active *oncology* immunotherapy target — anti-GARP antibodies, CAR-T, bispecifics — but these aim to *inhibit* GARP and are unrelated to treating GARP-deficiency syndrome.)

**Experimental outlook:** As a monogenic LoF disorder, it is conceptually a candidate for future gene-replacement approaches, but the congenital/developmental timing of the palatal defect limits postnatal correction of already-formed malformations.

### 13. Prevention

- **Primary prevention:** none at the population level. For known-carrier couples, **preimplantation genetic testing (PGT)** and **prenatal diagnosis** can prevent affected births.
- **Secondary prevention:** **cascade carrier testing** in consanguineous families with a known variant; early ophthalmologic screening in an at-risk newborn to catch progressive retinopathy.
- **Tertiary prevention:** timely palatoplasty, retinal intervention, and developmental therapy to prevent complications (malnutrition, aspiration, vision loss, functional decline).
- **Counseling:** **genetic counseling** is central — autosomal-recessive 25% recurrence risk; discussion of consanguinity.
- **Immunization / public health / environmental interventions:** not applicable.

### 14. Other Species / Natural Disease

- **Model species:** ***Mus musculus*** (NCBI Taxon:10090) — *Garp/Lrrc32* knockout. No naturally occurring animal disease (OMIA) is documented for this syndrome.
- **Orthologous gene:** mouse **Lrrc32/Garp**; the gene and its TGF-β–presenting function are **evolutionarily conserved**.
- **Comparative pathology:** the mouse null reproduces the **cleft palate** but is **neonatal-lethal**, so it does not model retinopathy or developmental delay. **Zoonotic/cross-species transmission:** not applicable (genetic disorder).

### 15. Model Organisms

- **Model type / system:** mammalian — **mouse *Garp/Lrrc32* knockout** (constitutive null). In vitro/ex vivo palatal shelf cultures and MEE cell assays supplement the model.
- **Genetic models available:** constitutive knockout demonstrated; conditional/tissue-specific alleles would be needed to bypass neonatal lethality (see follow-up).
- **Phenotype recapitulation:** **Good for the palatal phenotype** — the KO shows isolated secondary palate fusion failure with reduced MEE apoptosis and pSMAD2, phenocopying *Tgfb3*-null mice. **Poor for ocular/neurodevelopmental phenotypes** — death within 24 h of birth precludes their assessment.
- **Applications:** dissecting GARP → latent-TGF-β3 → SMAD2 → MEE-apoptosis axis in palatogenesis; testing whether TGF-β pathway restoration rescues palate fusion.
- **Resources:** MGI (mouse), IMPC/KOMP for allele availability.

---

## Mechanistic Model / Interpretation

```
   Biallelic LoF in LRRC32 (p.Arg544Ter  /  conserved Ile→Thr missense)
                                │
                                ▼
             Loss / severe reduction of functional GARP protein
                                │
                                ▼
      Failure to present membrane-bound LATENT TGF-β on the cell surface
              (TGF-β3 in palatal epithelium; TGF-β1 in immune cells)
                                │
                                ▼
        No integrin-αvβ8–mediated activation → ↓ mature TGF-β locally
                                │
                                ▼
                 ↓ TGF-β receptor engagement → ↓ SMAD2/3 phosphorylation
                                │
        ┌───────────────────────┼─────────────────────────────┐
        ▼ (DEMONSTRATED)        ▼ (INFERRED)                   ▼ (INFERRED)
  ↓ apoptosis of palatal   disrupted retinal          impaired CNS
  medial edge epithelium   vascular/neuroepithelial   development
        │                  development                        │
        ▼                        ▼                            ▼
   CLEFT PALATE          PROLIFERATIVE RETINOPATHY     DEVELOPMENTAL DELAY
 (phenocopies Tgfb3-null)                          (± growth retardation,
                                                     dysmorphism — 2022 pt)
```

The **upstream, demonstrated** portion of this chain (mutation → loss of GARP → loss of surface latent TGF-β3 → ↓SMAD2 → ↓MEE apoptosis → cleft palate) rests on direct experimental evidence in the mouse. The **downstream retinal and neurodevelopmental branches are inferred** from (a) the established requirement of TGF-β signaling for retinal and CNS development and (b) the co-segregation of these features with the biallelic *LRRC32* genotype in humans. The consistency of a single, well-understood signaling deficit across all three affected tissues makes the unified GARP–TGF-β model parsimonious and compelling, while honestly flagging that the ocular and neural mechanisms have not been directly proven in this disease.

---

## Evidence Base

| PMID | Title (abbrev.) | Evidence type | Role in this report |
|---|---|---|---|
| [30976112](https://pubmed.ncbi.nlm.nih.gov/30976112/) | *Homozygous stop-gain variant in LRRC32... cleft palate, proliferative retinopathy, developmental delay* (Harel et al. 2019) | Human clinical/genetic | **Foundational** — establishes gene–disease link, triad, TGF-β rationale, mouse lethality |
| [35656379](https://pubmed.ncbi.nlm.nih.gov/35656379/) | *A Novel Homozygous Missense Variant in LRRC32* (Hexner-Erlichman et al. 2022) | Human clinical/genetic | **Confirmatory** — 2nd family, allelic heterogeneity, phenotype expansion |
| [28912269](https://pubmed.ncbi.nlm.nih.gov/28912269/) | *GARP positively regulates TGFβ3 and is essential for mouse palatogenesis* (Wu et al. 2017) | Model organism/in vitro | **Mechanistic core** — GARP→latent-TGFβ3→SMAD2→MEE apoptosis; phenocopies Tgfb3-null |
| gnomAD v4 | *LRRC32* constraint & allele frequencies | Computational/population | Recessive-compatible constraint; ultra-rare allele, no homozygotes |

**Supporting context (GARP–TGF-β axis biology).** Multiple recent structural and immunological studies corroborate that GARP presents latent TGF-β on the cell surface and that activation is integrin-dependent — e.g., cryo-EM/allostery work showing αvβ8-mediated activation of L-TGF-β1/GARP ([PMID: 39288764](https://pubmed.ncbi.nlm.nih.gov/39288764/)), and reviews/therapeutic studies confirming GARP (LRRC32) as the docking receptor presenting latent TGF-β on Tregs and platelets ([PMID: 35898500](https://pubmed.ncbi.nlm.nih.gov/35898500/); [PMID: 36928178](https://pubmed.ncbi.nlm.nih.gov/36928178/)). These strengthen the biochemical plausibility of the disease mechanism, although they address immuno-oncology rather than the developmental syndrome directly.

**Challenges / caveats to the model.** Newer "dynamic allostery" data suggest mature TGF-β may signal *without physical release* from the latent complex ([PMID: 39288764](https://pubmed.ncbi.nlm.nih.gov/39288764/)); this refines but does not overturn the conclusion that GARP loss impairs TGF-β activation. The extensive PVR (proliferative vitreoretinopathy) literature involving TGF-β-driven RPE epithelial–mesenchymal transition ([PMID: 42285191](https://pubmed.ncbi.nlm.nih.gov/42285191/); [PMID: 40466854](https://pubmed.ncbi.nlm.nih.gov/40466854/)) concerns *acquired adult* retinopathy and is mechanistically distinct from the *congenital* retinopathy in this syndrome — a reminder that "proliferative retinopathy" here should not be conflated with adult PVR.

---

## Limitations and Knowledge Gaps

1. **Extreme rarity (~4 patients).** All clinical inferences rest on a handful of individuals from consanguineous families; prevalence, incidence, sex ratio, penetrance, expressivity, and natural history are essentially undefined.
2. **Ocular and neurodevelopmental mechanisms are inferred, not demonstrated.** The mouse null's neonatal lethality prevents modeling of retinopathy and developmental delay; no tissue-specific evidence links GARP loss to these features directly.
3. **No confirmed OMIM phenotype / Orphanet / ICD unified code** was identified for the triad syndrome, complicating standardized annotation.
4. **No treatment evidence base.** Management is extrapolated from component-condition standards; no outcome, response-rate, or QoL data specific to this syndrome exist.
5. **Genotype–phenotype correlation is unresolved.** Whether the missense (2022) vs. nonsense (2019) alleles produce systematically different severity (e.g., the added growth retardation) cannot be determined from two families.
6. **Human residual function unexplained.** Why humans survive infancy while complete mouse nulls die within 24 h is unknown (hypomorphic alleles? species differences in GARP dependence?).

---

## Proposed Follow-up Experiments / Actions

1. **Conditional/tissue-specific mouse models** (e.g., retina- and CNS-specific *Lrrc32* knockouts, or hypomorphic/knock-in alleles mimicking the human p.Arg544Ter and Ile→Thr variants) to bypass neonatal lethality and **directly test the retinal and neurodevelopmental branches** of the causal chain.
2. **Functional validation of the missense allele** — express the conserved Ile→Thr variant in cells and assay surface presentation of latent TGF-β and SMAD2 activation to confirm loss-of-function and quantify residual activity relative to the nonsense allele.
3. **Patient registry / GeneMatcher outreach** to identify additional families, enabling genotype–phenotype correlation, penetrance/expressivity estimates, and natural-history documentation.
4. **iPSC-derived retinal organoids and cortical organoids** from patient cells (or CRISPR-engineered *LRRC32* nulls) to model the human-specific ocular and neural phenotypes in vitro and probe TGF-β/SMAD signaling deficits.
5. **Formal variant curation** in ClinVar/ClinGen and assignment/confirmation of OMIM and Orphanet identifiers to standardize the disease entry.
6. **Ophthalmologic natural-history study** in any identified patients to define the trajectory of the proliferative retinopathy and optimal intervention windows.

---

*Report compiled from a five-iteration autonomous investigation. Evidence sources are distinguished as human clinical (PMID 30976112, 35656379), model organism/in vitro (PMID 28912269), and computational/population-genetic (gnomAD v4). Findings F001–F004 are recorded in the knowledge state with verified abstract quotations.*


## Artifacts

- [OpenScientist final report](Cleft_Palate_Proliferative_Retinopathy_And_Developmental_Delay-deep-research-openscientist_artifacts/final_report.html)
- [OpenScientist final report](Cleft_Palate_Proliferative_Retinopathy_And_Developmental_Delay-deep-research-openscientist_artifacts/final_report.pdf)

## Reference Validation

Checked with `linkml-reference-validator` 0.2.1.

| Outcome | Count |
| --- | --- |
| References checked | 8 |
| Resolved | 8 |
| Unresolved (possible confabulation) | 0 |
| Unverifiable | 0 |
| References weighed for topical relevance | 8 |
| On topic | 3 |
| Off topic | 1 |

### References that may not be about this subject

These identifiers resolve, so they are not fabrications, but the records they resolve to share almost none of this report's vocabulary. That is a clue and not a verdict - a paper can be relevant in ways its title and abstract do not spell out - so read them before deciding:

- `PMID:35898500` (3 mentions) - GARP as a Therapeutic Target for the Modulation of Regulatory T Cells in Cancer and Autoimmunity.
  - shared terms: garp

Weighed against this report's own most characteristic terms: `palate`, `retinopathy`, `garp`, `developmental`, `lrrc32`, `cleft`, `tgf`, `delay`, `mouse`, `syndrome`, `loss`, `genetic`, `proliferative`, `disease`, `patient`, `retinal`, `phenotype`, `disorder`, `clinical`, `familie`.

All extracted references resolved successfully.
Resolving is not the same as being relevant, though - see the references listed above as possibly off topic.

## Term Validation

Checked with `linkml-term-validator` 0.4.5, through the `ols:` adapter.

| Outcome | Count |
| --- | --- |
| Terms checked | 22 |
| Resolved | 20 |
| Unresolved (possible confabulation) | 0 |
| Obsolete | 0 |
| Unverifiable | 2 |
| Terms whose name was checked | 10 |
| Terms named correctly | 5 |
| Terms named as a **different** term | 2 |
| Terms whose name is worth a second look | 3 |

### Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

- `HP:0000175` (1 mention) - the report calls it "Physical malformation"; HP calls it **Cleft palate**
- `HP:0001999` (1 mention) - the report calls it "Physical manifestation"; HP calls it **Abnormal facial shape**

### Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a *related* synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

- `GO:0060021` (1 mention) - the report calls it "palate development"; GO calls it **roof of mouth development**, and lists "palatum development" among its other names
- `UBERON:0001716` (2 mentions) - the report calls it "palate", "Primary organs:** secondary **palate"; UBERON calls it **secondary palate**
- `UBERON:0000955` (2 mentions) - the report calls it "brain/CNS"; UBERON calls it **brain**

### Terms named inconsistently

The report gives these identifiers more than one name of its own:

- `HGNC:4161` - called "LRRC32", "Gene:** *LRRC32"
- `UBERON:0001716` - called "palate", "Primary organs:** secondary **palate"

### Prefixes with no resolver

Terms carrying these prefixes were not checked either way, because no configured ontology covers them. An unrecognised prefix may name an ontology this run could not reach as easily as one that does not exist, so nothing here is evidence of fabrication: `Taxon`.